Identification of novel series of pyrazole and indole-urea based DFG-out PYK2 inhibitors
Authors:
- Samit K. BhattacharyaSBSamit K. Bhattacharya
- Gary E. AspnesGAGary E. Aspnes
- Scott W. BagleySBScott W. Bagley
- Markus BoehmMBMarkus Boehm
- Arthur D. BrosiusABArthur D. Brosius
- Leonard BuckbinderLBLeonard Buckbinder
- Jeanne S. ChangJCJeanne S. Chang
- Joseph DibrinoJDJoseph Dibrino
- Heather EngHEHeather Eng
- Kosea S. FrederickKFKosea S. Frederick
- David A. GriffithDGDavid A. Griffith
- Matthew C. GrifforMGMatthew C. Griffor
- 1 December 2012
- journal article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 22 (24) , 7523-7529
Abstract
No abstract availableKeywords
This publication has 22 references indexed in Scilit:
- Quantifying the chemical beauty of drugsNature Chemistry, 2012
- A reappraisal of generic bisphosphonates in osteoporosisOsteoporosis International, 2011
- Emerging Targets in Osteoporosis Disease ModificationJournal of Medicinal Chemistry, 2010
- Targeting Pyk2 for therapeutic interventionExpert Opinion on Therapeutic Targets, 2009
- Managing osteoporosis: Challenges and strategiesCleveland Clinic Journal of Medicine, 2009
- Structural Characterization of Proline-rich Tyrosine Kinase 2 (PYK2) Reveals a Unique (DFG-out) Conformation and Enables Inhibitor DesignJournal of Biological Chemistry, 2009
- Trifluoromethylpyrimidine-based inhibitors of proline-rich tyrosine kinase 2 (PYK2): Structure–activity relationships and strategies for the elimination of reactive metabolite formationBioorganic & Medicinal Chemistry Letters, 2008
- The influence of drug-like concepts on decision-making in medicinal chemistryNature Reviews Drug Discovery, 2007
- Mechanisms of Anabolic Therapies for OsteoporosisNew England Journal of Medicine, 2007
- Proline-rich tyrosine kinase 2 regulates osteoprogenitor cells and bone formation, and offers an anabolic treatment approach for osteoporosisProceedings of the National Academy of Sciences, 2007